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Abstract: The blood–brain barrier (BBB) is a natural obstacle for drug delivery into the human
brain, hindering treatment of central nervous system (CNS) disorders such as acute ischemic stroke,
brain tumors, and human immunodeficiency virus (HIV)-1-associated neurocognitive disorders.
Poly(lactic-co-glycolic acid) (PLGA) is a biocompatible polymer that is used in Food and Drug
Administration (FDA)-approved pharmaceutical products and medical devices. PLGA nanoparticles
(NPs) have been reported to improve drug penetration across the BBB both in vitro and in vivo.
Poly(ethylene glycol) (PEG), poly(vinyl alcohol) (PVA), and poloxamer (Pluronic) are widely used as
excipients to further improve the stability and effectiveness of PLGA formulations. Peptides and
other linkers can be attached on the surface of PLGA to provide targeting delivery. With the newly
published guidance from the FDA and the progress of current Good Manufacturing Practice (cGMP)
technologies, manufacturing PLGA NP-based drug products can be achieved with higher efficiency,
larger quantity, and better quality. The translation from bench to bed is feasible with proper research,
concurrent development, quality control, and regulatory assurance.
Keywords: poly(lactic-co-glycolic acid) (PLGA); blood–brain barrier (BBB); current Good Manufac-
turing Practice (cGMP); Food and Drug Administration (FDA); nanotechnology
1. Blood–Brain Barrier (BBB) and Drug Delivery
Compared with other therapeutic areas, drug development is more challenging for
brain diseases such as brain cancers, Alzheimer’s diseases (AD), acute ischemic stroke, and
human immunodeficiency virus (HIV)-1-associated neurocognitive disorders (HAND) [1–4].
Many systemically administered drug products cannot pass the BBB [5]. The BBB restricts
the entry of compounds into the central nervous system (CNS) through the presence of
brain microvascular endothelial cells, pericytes, perivascular astrocytes, and tight junc-
tions. In addition, the presence of efflux transporters at the BBB has been recognized as
a key element to poor drug penetration [6,7]. ATP-binding cassette (ABC) membrane-
associated transporters, such as P-glycoprotein (P-gp), breast cancer resistance protein
(BCRP), and multidrug resistance-associated protein (MRP1) show significant expressions
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at the BBB, protecting the brain from potential harmful endogenous and exogenous sub-
stances [6,7]. As a result, the BBB only selectively transports molecules such as certain
amino acids, sugars, and gaseous molecules (e.g., oxygen and carbon dioxide) into the
brain [8]. For example, antiretroviral drugs (ARVs) have shown to be effective in managing
HIV-1 [9]. However, due to the inability of ARVs to cross the BBB, they are not highly rec-
ommended clinically for the treatment of HAND. Studies showed that, upon boosting with
a pharmaco-enhancer, i.e., ritonavir, ARVs including indinavir, elvitegravir, and lopinavir
reached therapeutic concentrations in plasma but did not reach therapeutic concentration
in the brain, indicating the challenges of delivering drugs to the CNS [10,11].
2. Strategies to Cross BBB
Several strategies have been used to improve drug delivery to the brain. Efforts
have been made for the development of inhibitors for ABC transporters due to their high
expressions on the BBB [2,12,13]. Studies showed that blocking ABC transporters may
significantly improve drug penetrations across the BBB. However, this method has not
been used clinically due to the wide distribution of ABC transporters throughout the body,
the potential toxicity of inhibitors, and unexpected drug–drug interactions [12]. Another
approach is the “BBB opening” approach. Opening the BBB can be achieved by using a
hyperosmotic solution to shrink the endothelial cells or using certain cytotoxic agents to
disrupt the BBB tight junctions [12,13]. However, opening the tight junctions of the BBB is
risky clinically because it may also allow the entry of harmful components into the brain
and cause side-effects such as seizures and other long-term neurological complications [12].
Moreover, the development of prodrugs to increase their capacity to penetrate the BBB
is another potential delivery approach [12]. Prodrugs can be synthesized with sufficient
lipophilicity to facilitate the crossing of the endothelial cell membrane and release the
parent ARVs into the brain. However, developing prodrugs as a delivery strategy needs a
full evaluation of toxicity, cost, and efficacy, as prodrugs are considered to be a separate
chemical entity.
A nanoparticle (NP)-based drug delivery system is considered a promising option
to improve drug delivery to the brain [3]. NP-based formulations are usually a colloidal
system made of polymers, lipids, or other large macromolecules such as albumin. A
therapeutic agent may be released through diffusion or erosion of the matrix [14]. The
NP-based delivery system can cross the BBB through membrane transcytosis, bypass efflux
transporters, and effectively deliver the therapeutic molecule to the CNS [3]. NPs that
have been studied for brain delivery include polymeric NPs such as poly(D,L-lactide-co-
glycolide) (PLGA) [15,16] and poly(butyl-cyanoacrylate) (PBCA) NPs [17,18], magnetic
NPs (MNPs) composed of an iron oxide core [18], lipid-based nanoformulations such
as solid lipid nanoparticles (SLN) and liposomes [12,18], and polymeric micelles-based
nanoformulations such as Pluronic micelles [12]. Extracellular vesicles (EVs), liposome-like
natural carriers, have drawn attention for delivering drugs into the brain as a potential
alternative to NPs [19–21].
3. Introduction of Physical, Chemical, and Biological Characteristics of PLGA Polymer
3.1. Synthesis of PLGA Polymer
PLGA is a synthetic copolymer composed of lactic and glycolic acid polyesters. Synthe-
sis of PLGA is commonly achieved either through ring-opening polymerization reactions
of lactide and glycolide [22,23] or through polycondensation reactions of lactic acid and
glycolic acid to form PLA and PGA block polymers [24,25]. Ring-opening polymeriza-
tion processes can be used to generate high-molecular-weight PLGA polymers [26], while
polycondensation processes are more suitable for the synthesis of low-molecular-weight
polymers [27].
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3.2. Physicochemical and Biomolecular Characteristics of PLGA
PLA can exist in D- or L-lactic acid, as well as in D,L-lactic acid, configurations. Homo
isomeric PLAs are more crystalline due to the uniform spatial arrangement leading to
tighter packing of the polymer chains [28,29]. On the other hand, glycolic acid has no
asymmetric carbon; thus, PGA exists only in a highly crystalline form. PLA is more
hydrophobic than PGA due to its methyl side groups. As a result, the hydrophobicity and
crystallinity of PLGA can be controlled through the ratio of lactide to glycolide. PLGA
physicochemical properties, such as mechanical strength, solubility, rate of hydration, rate
of hydrolysis, and glass transition temperature (Tg), are heavily influenced by crystallinity
and hydrophobicity [30–32]. PLGA with a high degree of crystallinity will have a higher
Tg and mechanical strength, as well as a decreased rate of hydration and hydrolysis.
In general, PLGA NPs are susceptible to clearance by the reticuloendothelial system
(RES) through opsonin-mediated phagocytosis [33]. RES elimination and biodistribution
of PLGA NPs depend on size, hydrophobicity, and surface charge. Cytotoxicity of PLGA
NPs was investigated in vitro by monitoring the cell viability of Caco-2 and HeLa cell
lines [34,35]. The study indicates that PLGA NPs at the concentration tested were not toxic
to cells as both cell lines retained over 75% viability. According to histopathology assays,
orally administered PLGA nanoparticles did not elicit adverse effects in mice [35]. Tissue
distribution analysis in mice indicated that most of the PLGA NPs were detected in the
liver, kidney, heart, and brain, with small amounts detected in plasma [35]. In aqueous
conditions, PLGA undergoes hydrolysis of its ester bonds. Hydrolytic biodegradation
of PLGA leads to nontoxic byproducts [36,37]. Several studies have investigated the
factors that affect PLGA biodegradation, including intrinsic properties such as hydration
rate, hydrophobicity/hydrophilicity, polymer chemical composition, molecular weight,
crystallinity, and Tg [38]. Moreover, external factors such as pH and chemical additives
were also shown to influence hydrolytic degradation [39].
4. PLGA NPs as a Brain Drug Delivery System
PLGA is a highly investigated polymer due to its ability to form NPs, micelles, and
microspheres, as it possesses the properties of biocompatibility, biodegradability, and
tolerability [40]. As drug delivery systems, PLGA NPs can be used to prepare controlled-
release dosage forms of small-molecule drugs, peptides, and nucleic acids [41]. Through
proper copolymerization with PEG and surface modifications with linkers, PLGA NPs
have been demonstrated as promising carriers for drug delivery across the BBB.
4.1. PLGA NPs Modifications and Mechanisms
PLGA NPs can be prepared through various processing methods including (1) double-
emulsion solvent evaporation [42], (2) single-emulsion solvent evaporation [43], (3) phase
separation [44], (4) spray-drying [45–47], (5) salting out [48,49], and (6) nanoprecipita-
tion [50,51]. Even though the names are different, processing methods focus on the self-
assembly characteristics of PLGA in aqueous solutions to finish the drug encapsulation [52–54].
Details of processing methods and potential scale-up technologies are discussed in Section 5.
PLGA NPs can cross the BBB passively or through active endocytosis mechanisms as
shown in Figure 1. Unmodified PLGA NPs cross the BBB primarily through passive inter-
nalization based on size, which was found to have low brain uptake. Several strategies have
been developed to improve the penetration of NPs into the brain. These strategies modify
NPs with components designed to take advantage of BBB endocytosis pathways. Modified
PLGA NPs have been designed to cross the BBB through adsorption-mediated transcy-
tosis (AMT) [55], carrier-mediated transport (CMT), and receptor-mediated transcytosis
(RMT) [56].
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Figure 1. Transport mechanisms of poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) to cross
the blood–brain barrier (BBB), including passive diffusion, adsorption-mediated transcytosis (AMT),
carrier-mediated transport (CMT), and receptor-mediated transcytosis (RMT).
PLGA NP surfaces are modified with positive charges that electrostatically interact
with negatively charged regions of the luminal surfaces, which helps PLGA to cross the
BBB. Several cationic modifications of PLGA NPs have been demonstrated to utilize the
AMT concepts to improve brain uptake. In CMT systems, PLGA NPs are modified with
membrane-permeable molecules such as amino acids, nutrients, and membranotropic pep-
tides, and they are able to transport cargo across the BBB endothelium. CMT systems also
include designs that take advantage of ABC transporters. With RMT, PLGA NPs are modi-
fied or covalently connected with ligands that target specific cell surface receptors known
to be BBB transport pathways. A search of the PubMed database with the keywords “PLGA
nanoparticles”, “BBB”, and “drug delivery” from 2015 to date returned 133 publications.
From the search results, only research articles that included BBB permeability studies of
control “unmodified” PLGA NPs and modified PLGA NPs are summarized in Table 1. Tan-
dem systems that utilized multiple modifications have been reported. Guarnieri et al. [57]
demonstrated the cooperative effects of glycoprotein H 625, a CMT modification with
iron-mimicking protein CRT and RMT modification, in enhancing PLGA NP permeation of
BBB. Liu et al. [58] developed a PLGA NP drug delivery system modified with angiopep-2
(RMT) and 1, 2-Dioleoyl-3-trimethylammonium-propane (AMT), for gefitinib and Golgi
phosphoprotein 3 for the treatment of glioblastoma. Intranasal [59–61] or subcutaneous [62]
administration of PLGA NP drug systems can bypass the BBB and avoid issues associated
with systemic administration.
4.2. PLGA–PEG Co-Polymeric NPs, Modifications, and Applications
To overcome its short half-life, PLGA is combined with polyethylene glycol (PEG) to
form PLGA–PEG copolymer NPs [63–65]. The PLGA–PEG copolymer is widely used in
pharmaceutical products and devices. Recently, several advancements have been made to
modify the surface of the PLGA–PEG NPs to further increase their ability to cross the BBB
and deliver drugs into the brain.
The favorable chemistry of the PLGA–PEG NPs makes them amenable for conjugation
with various peptides and linkers for use in the treatment of various neurodegenerative
diseases and glioma. Memantine is commonly used for the treatment of mild and moderate
AD. Encapsulating it in PLGA–PEG NPs using a double-emulsion method increased the
delivery to the target tissue with ameliorated pathological markers compared to free
memantine [66].
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Table 1. Summary of BBB permeability studies of unmodified and modified PLGA NPs.






TMC-modified PLGA NPs loaded with
coumarin exhibited increased uptake in
mouse brains vs. PLGA-NPs.
Neuroprotective effects of Q10 displayed by








Angiopep-2 modified PLGA NPs improved
DOX and siRNA cell uptake. In vivo study
showed that the ang-2-PLGA construct can
cross BBB.
[69] 8D3 monoclonalantibody Loperamide RMT
8D3 functionalized Loperamide-loaded PLGA
NPs produced a higher maximal possible
antinociceptive effect compared to
Loperamide-loaded NPs without 8D3.
[70] Lactoferrin, folic acid Etoposide RMT BBB permeability coefficient of PLGA NPsincreased twofold with Lf-and FA.
[71] OX26 monoclonalantibody 1Aβ5 peptide RMT
OX26 increased the uptake of PLGA NPs by
BBB endothelial cells which enhanced the
peptide transport.
[72] Lactoferrin Rotigotine RMT
Intranasal delivery of rotigotine to the brain
was more effective with Lf-PLGA NPs than
with PLGA-NPs.
[73] RVG29 Docetaxel RMT RVG29 PLGA NPs showed better BBBpenetration in vitro.
[74] OX26 monoclonalantibody Temozolomide RMT
OX26 functionalization enhanced TMZ
internalization in glioblastoma cells.
[75] Dendrimer cationizedalbumin Doxorubicin AMT
Cellular uptake and cell permeability of DOX
in dCatAlb-functionalized PLGA NP was
improved 1.59-fold and 1.49-fold, respectively,






The in vivo evaluation of TPGS–PLGA NPs
showed amplified accumulation (>800% after
96 h) of PTX in the brain tissue when
compared with bare NPs.
[77] Polysorbate 80 Rhynchophylline AMT
In an in vitro BBB model study,
functionalized PLGA NPs showed increased
transport across bEnd.3 cell monolayers.
1 Adsorption-mediated transcytosis (AMT), carrier-mediated transport (CMT), and receptor-mediated transcytosis (RMT).
Pioglitazone-loaded PLGA–PEG NPs produced by the solvent displacement technique
reduced amyloid burden and decreased memory impairment by increasing the rate of tran-
scytosis across BBB and slowly releasing pioglitazone in the target tissue [78]. Selegiline-
or donepezil-loaded PLGA–PEG NPs produced by the solvent evaporation method desta-
bilized the beta-amyloid formation in vitro [79,80]. Various natural compounds and drugs
encapsulated in PLGA–PEG NPs were shown to be effective in reducing AD pathology
in in vitro models [81]. The antinociceptive effect of loperamide was increased by two- to
threefold by encapsulation in a PLGA–PEG–PLGA triblock polymeric NPs coated with
poloxamer 188 or polysorbate 80 compared to unmodified NPs alone [82]. With peptides
as a modification on PLGA–PEG NPs, Hoyos-Ceballos et al. [35] showed that angiopep-2
conjugated to PLGA–PEG NPs increased their ability to cross the BBB in C57/BL6 mice.
PLGA–PEG NPs conjugated with B6 peptide increased the delivery of curcumin into the
CNS in an AD mouse model, showing a reduced expression of hallmark AD pathological
markers, including amyloid-beta, presenilin-1, phosphorylated tau, and beta-secretase 1,
compared to curcumin alone or NPs without B6 peptide [83].
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Surnar et al. [84] added a targeting function to PLGA–PEG NPs through conjugating
with a lipophilic triphenylphosphonium cation on the surface using a butylene linker.
This NP system, when loaded with either coenzyme Q10 or aspirin, was able to cross
the mitochondrial double membrane in endothelial cells and astrocytes to reduce the
oxidative stress, which is extremely valuable to treat HAND [84]. Yu et al. [85] optimized
the development of PLGA–PEG polymersomes conjugated on the surface with lactoferrin
as a brain targeted delivery system for peptides. They loaded the NPs with S14G-humanin
peptides which exerted a protective effect by decreasing the caspase-3 and bax expression in
the rat hippocampus neurons treated with amyloid-beta. Similarly, Bi et al. [72] showed that
PLGA–PEG NPs modified with lactoferrin on their surface were able to deliver rotigotine
into the striatum by intranasal administration for potential use in Parkinson’s disease (PD).
Lectin-conjugated PLGA–PEG NPs were able to deliver the basic fibroblast growth factor
peptide cargo across the BBB after intranasal administration [86]. Similarly, odrranalectin-
conjugated PLGA–PEG NPs were able to efficiently deliver the encapsulated urocortin
peptide into the brain as a treatment for PD [86]. Recently, Amanda et al. [87] showed
that a modified PLGA–PEG NP system encapsulating epigallocatechin gallate was able to
ameliorate neurological deficits induced by 3-nitropropionic acid in Huntington’s disease
mouse model.
Glioma is an invasive carcinoma of the brain with an average life expectancy of ap-
proximately 12–14 months and has poor survival rates [88]. NP systems were used to
deliver drug into the brain. Receptor-mediated transcytosis provides a chance to target
specific receptors expressed on the surface of cancer cells through ligand–receptor in-
teractions. Cui and coworkers [89] developed a novel dual-targeting PLGA–PEG-based
magnetic NP system that crosses the BBB by conjugating transferrin receptor-binding
peptide T7 on the surface and encapsulating curcumin and paclitaxel into the NP hy-
drophobic core. Compared to free drugs, the mice with orthotopic glioma survived with
the NP system. Similarly, doxorubicin and tetrahydrocurcumin encapsulated in transferrin-
modified PLGA–PEG NPs showed effectiveness in reducing the glioma tumor volume in
combination with radiotherapy [90]. Lactoferrin-conjugated PLGA–PEG NPs increased the
brain concentrations of shikonin, a naphthoquinone pigment for the potential use in the
treatment of glioma [91]. The iNGR-conjugated PLGA–PEG-based NP system designed
to target the glioma tumor vessel was effective in delivering the paclitaxel to the glioma
parenchyma. Moreover, this NP system was able to travel deeper into the glioma to in-
crease survival rates [92]. Farnesyl thiosalicylic acid, an inhibitor of Ras oncoprotein, was
shown to be effective against glioblastoma when administered as PLGA–PEG-based hybrid
NPs, which contained 1,2-distearoyl-glycerol-3-phosphoethanolamine and 1,2-dioleoyl-3-
trimethylammonium-propane [93].
Another strategy to treat glioma is to target the genes overexpressed in malignant
glioma cells. Cyclic hexapeptide-conjugated PLGA–PEG NPs were able to deliver curcumin
to the glioma by binding to integrins that are upregulated on the glial cell surface [94].
A nine amino acid linear peptide (Pep-1) targeting the interleukin 13 receptor α2 overex-
pressed on the surface of gliomas was conjugated to PLGA–PEG NPs [95]. Modification
with CGKRK peptide, which targets the heparan sulfate expressed on neovascular endothe-
lial cells, resulted in a dual-targeted approach and increased the median survival time in
intracranial glioma mice [96]. A biodegradable PLGA–PEG polymer NP system targeting
the Fn14 receptor overexpressed on the brain tumor cells was generated by conjugating
PLGA–PEG NPs with ITEM4 monoclonal antibody. The half-life of these NPs was more
than doubled compared to nontargeted PLGA–PEG NPs [97].
4.3. PLGA NPs for Theranostic Applications
Theranostic represents a novel and powerful emerging platform that integrates tar-
geted therapeutic entities with noninvasive imaging and has the great potential to per-
sonalize and advance medicine. Several nanosized delivery vehicles, including gold and
iron-oxide nanoparticles, as well as quantum dots, have been extensively studied for
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theranostic applications [98–100]. Given safety concerns, off-target effects, and slow ex-
cretion kinetics from the body, risks may limit its use in the course of diseases. PLGA
NP-based theranostic applications can deliver a therapeutic agent while simultaneously
monitoring therapy response in real time [101,102]. Contrast agents, such as the radionu-
clide or fluorophore, play a critical role in enabling visualization of a target with con-
ventional imaging techniques, e.g., magnetic resonance imaging (MRI), optical imaging,
and X-ray computed tomography. Contrast agents including superparamagnetic iron
oxide (SPIO) and gadolinium were shown to be encapsulated with polymeric nanopar-
ticles [103]. For example, SPIO and chemotherapy drug docetaxel can both be directly
encapsulated with PLGA [104]. Similarly, an human epidermal growth factor receptor
2 (HER2)-targeted PLGA–PEG block copolymer nanoparticle, upon encapsulation with
MnFe2O4 and doxorubicin, was designed to target breast cancer in vivo [105]. Encapsu-
lation of anticancer drug N′-(2-Methoxybenzylidene)-3-methyl-1-phenyl-H-Thieno[2,3-
c]Pyrazole-5-Carbohyd-razide (MTPC) with plasmonic gold nanorods in PLGA-b-PEG
polymeric nanospheres enhanced both biodistribution and pharmacokinetics of the MTPC
in tumor-bearing mice [106]. Similar to MRI, radionuclide imaging has high sensitivity with
no tissue-penetration limitations. Several radionuclide compounds have been extensively
studied along with PLGA with the goal of formulating a robust nano delivery system [107].
For instance, Wang and colleagues [108] designed PLGA-lipid hybrid nanocarriers for
theranostic therapy, encapsulating an anticancer agent in the matrix, while the lipid shell
was chelated with indium-111 or yttrium-90 as radiotherapy agents. Shao et al. [107]
demonstrated the therapeutic effect of 32P-CP-PLGA brachytherapy for glioma with the in-
tegrin αvβ3-targeted radiotracer 68Ga-3PRGD2. Press and colleagues [109] demonstrated
the cell-type-specific delivery of short interfering RNAs by covalent conjugation of DY-635
fluorescent dye with known hepatobiliary clearance to a PLGA, which allowed them to
monitor distribution, uptake, and clearance of short hairpin RNA from the target organ.
The major hurdle for the treatment of neurodegenerative diseases is to design therapeutic
molecules in a way that it can cross the BBB. Zhang et al. [86] showed that the lectin-
modified PLGA nanoparticle encapsulated with basic fibroblast growth factor enhanced
drug delivery to the brain, supporting the role of the PLGA NP-based drug delivery system
for CNS disorders. Therefore, nanocarriers based on PLGA offer biocompatibility, good
stability, and regulated drug release rate and represent an excellent and emerging platform
in theranostic medicine.
5. From Research and Development (R&D) to cGMP: Technologies for Scale-Up
To promote promising formulations from the R&D stage to clinical trials, drug prod-
ucts need to be manufactured under certain guidelines. Current Good Manufacturing
Practice (cGMP) are regulations enforced by the FDA to ensure the quality of pharmaceuti-
cal products [110]. Most PLGA NP-based pharmaceutical products or medical devices are
either injectable or implantable [111]. Therefore, sterility and potency are among the top-
quality aspects to be considered for PLGA NPs. Per cGMP regulations, sterile products must
be manufactured in a registered sterile facility [19]. Furthermore, facilities need to show
that a sterile environment is properly maintained with validated sanitization [112]. PLGA
NP-based pharmaceutical products have several steps during production: (1) dissolution
and mixture of the active pharmaceutical ingredient (API) and PLGA; (2) stabilization of
the mixture and removal of organic solvents; (3) separation of free API from PLGA–API
product; (4) sterilization; (5) fill-finish. Table 2 presents selected publications showing
processing details in the R&D stage.
For scale-up, dissolution of API/PLGA is achieved using stainless-steel tanks with
temperature control through double jacketing. Mechanical motors are built into most tanks
for light agitation. Since PLGA is not water-soluble, while lipophilic APIs can be dissolved
concurrently, hydrophilic ones need to be dissolved separately from PLGA. To stabilize
the formulation, PVA is mostly used as a surfactant. Moreover, poloxamer (also named
Pluronic), polysorbate, sodium cholate, and D-α-tocopheryl pol-yethylene glycol succinate
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(TPGS) are also reported as promising alternatives. Subsequently, aggressive agitation
is needed to decrease the mixture droplets’ particle size. High-pressure homogenization
is widely used in cGMP production, and this technology is also reported with details in
Table 2. To remove organic solvents, most publications took advantage of the different
boiling points in water and organic solvents through overnight stirring. While this method
is useful on the R&D scale, GMP-scale production uses vacuum-assisted rotary evaporation,
which is more efficient and easier to validate.
Since PLGA NP-based pharmaceutical products represent a self-assembly drug deliv-
ery system, it is critical to separate free APIs from encapsulated ones. The encapsulation
rate is one key quality control aspect due to the concern of toxicity. In Table 2, most
publications used centrifugation, assisted by filters and membranes. In cGMP production,
diafiltration is the technology preferred due to its higher recovery rate and better cost-
effectiveness compared to centrifugation. Diafiltration uses a semipermeable membrane to
separate the free drug from encapsulated drug based on the difference in cutoff molecular
weight. Furthermore, diafiltration can form a closed system to return encapsulated prod-
ucts to the container for reprocessing until a target encapsulation rate is reached with the
highest yield [113].
Among popular terminal sterilization methods, steam sterilization (autoclave) and
gamma irradiation were reported to cause degradation of PLGA [114]. Vaporized ethy-
lene oxide is commonly used for sterile gowning materials, but its residual is toxic if
injected [115]. Electron beam technology is less aggressive than gamma irradiation but can
still cause degradation of PLGA [116]. According to the available technologies for cGMP
production and the particle size distribution reported from literature, sterile filtration is the
best option for PLGA NP-based products. However, a filter compatibility study needs to
be performed for validation purposes to minimize API retaining during filtration.
Depending on the concentration of PLGA NP-based pharmaceutical products, the
solution may be free-flowing or with high viscosity. High viscosity is a problem for both
sterile filtration and automatic filling systems. Filters may be clotted during filtration,
the filling accuracy may be compromised, and rejection of vials may occur frequently.
Therefore, an engineering fill-finish of placebo is strongly recommended as an industry
standard for PLGA NP-based drug products. According to the stability data, lyophilization
is recommended for extended shelf life. As presented in Table 2, lyophilization was
reported using sugar molecules as cryoprotection. In cGMP production, lyophilization
is considered a sterile product and is performed in the last step. The difficult part of
lyophilization is the programming of cycles to minimize the moisture content (<5%, w/w).
Figure 2 is a concept flowchart for cGMP production of PLGA NP-based pharmaceuti-
cal products. The steps in Figure 2 are provided on the basis of the details in Table 2 and
the industry standards under cGMP guidelines.
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Table 2. Processing details for PLGA NP-based systems from publications.
Ref API API Solvent PLGA Solvent PrimaryAqueous
Secondary
Aqueous Purification
[117] Doxorubicin 0.001 N HCl Dichloromethane 1% PVA in PBS
[118] Transferrin RH buffer(pH = 7.4) Acetone/ethanol Water
[66] Memantine/rhodamine Water Ethyl acetate PVA solution 0.3% PVA
Centrifuge:
15,000 rpm, 20 min
[119] Rhodamine-6G PBS Ethyl acetate 1% PVA Centrifuge
[80] Donepezil Water Dichloromethane 2% Pluronic F68 0.5% PluronicF68
Centrifuge:
20,000× g, 20 min
[120] Doxorubicin Water Dichloromethane Water





[121] Elaprase® Water Dichloromethane Water 1% PVA
Centrifuge:
17,000 rpm, 10 min,
5 ◦C
[122] Olanzapine Acetonitrile Acetonitrile 0.25%Poloxamer 407
Centrifuge:
25,000 rpm, 4 ◦C
[71] iAβ5 Chloroform Chloroform 0.1% PluronicF127
Centrifuge:
14,300× g, 40 min















13,000 rpm, 30 min,
4 ◦C
[126] Curcumin Acetonitrile Acetonitrile Lipids, EtOH inwater Centrifuge: 10 kDa












35,000 rpm, 1 h













15,000× g, 1 h, 5 ◦C
[67] Coenzyme Q10 Acetone Acetone 0.02% vitamin ETPGS
Centrifuge:
15,000× g, 15 min,
20 ◦C
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Figure 2. Concept flowchart of cGMP operations for PLGA NP-based drug products.
6. Quality and Regulatory Assurance
The quality of nano-based pharmaceutical products is a learning curve for both
manufacturers and regulatory agencies. In 2006, the FDA initialed the Nanotechnology
Task Force to improve the service for nano-based products. After its first public report in
2007, FDA published the second report in 2020, emphasizing its commitment to nano-based
products. Among the five published guidance for industry regarding nanomaterials, two
of them were designed for pharmaceutical and medical products. Another draft guidance
is under review for drug products and biological products. On the basis of the above
documents, FDA will not accept or reject nanotechnology products according to category.
Instead, FDA will conduct a comprehensive review to make a science-focused decision.
Size distribution is the FDA’s first consideration among all factors. Dynamic light
scattering (DLS) technology is widely used for quality control purposes. Furthermore,
a chromatography-based assay of APIs and encapsulation rate is critical to avoid toxic-
ity. United States Pharmacopeia (USP) monograph “Goserelin Implants” also requests
HPLC results to provide the retention time of PLGA, which is not rare for quality control
of polymers [128]. Table 3 is a summary of the most needed in-process tests and final
release tests.
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Table 3. In-process and release tests for PLGA NP-based drug products.
Purpose USP Chapter Test
IPC-1
N/A High-performance liquid chromatography








<467> Residual organic solvents
<281> Residue on ignition
<731, 921> Loss on drying for lyophilized products




<788> Particulate matter for injection
<1207> Uniformity of dosages
During the Covid-19 pandemic, several liposome-based vaccines were approved for
emergency use [129]. Liposome-based pharmaceutical products have similar self-assembly
characteristics compared to PLGA NP-based ones. Therefore, their quality and regulatory
focus should be similar. Furthermore, the success of vaccines also revealed the possibility
of PLGA NP-based products to be approved through facilitated regulatory pathways,
especially for emergency purposes under global regulatory systems [130,131].
7. Conclusions
This review presented recent progress in PLGA NPs as a vehicle to deliver drug to the
brain in a controllable and targeted manner. Unlike most NPs, PLGA NPs show a promising
future to become a clinically and commercially feasible drug delivery system. PLGA has
been approved for both pharmaceutical products and medical devices, which provides
clear quality control, quality assurance, and regulatory requirements for future products.
Furthermore, the improvement of cGMP technologies, especially those in nanomedicines
and sterile injectables, has also removed most obstacles for PLGA NPs. Even though safety
is not the major concern, clinical trials are needed to monitor the efficacy and toxicity of
PLGA NPs. Uncertainties, such as drug encapsulation rate, assembly stability, particle size
distribution stability, and in vivo pharmacokinetics, may be the focus for future research
and development.
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